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Abstract
The urgent need for new treatments for the chronic lung disease idiopathic pulmonary
fibrosis (IPF) motivates research into antagonists of the RGD binding integrin αvβ6, a protein
linked to the initiation and progression of the disease. Molecular dynamics (MD) simulations
of αvβ6 in complex with its natural ligand, pro-TGF-β1, show the persistence over time of
a bidentate Arg-Asp ligand-receptor interaction and a metal chelate interaction between an
aspartate on the ligand and an Mg2+ ion in the active site. This is typical of RGD binding
ligands. Additional binding site interactions, which are not observed in the static crystal
structure, are also identified. We investigate an RGD mimetic, which serves as a framework
for a series of potential αvβ6 antagonists. The scaffold includes a derivative of the widely
utilised 1,8-naphthyridine moiety, for which we present force field parameters, to enable MD
and relative free energy perturbation (FEP) simulations. The MD simulations highlight the
importance of hydrogen bonding and cation-π interactions. The FEP calculations predict
relative binding affinities, within 1.5 kcal mol−1, on average, of experiment.
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Integrin αvβ6 is a transmembrane, heterodimeric protein. The involvement of integrins in the
progression of several tumour types and diseases including idiopathic pulmonary fibrosis (IPF)
makes them important targets for the development of new drug compounds.1–3 IPF is a chronic
disease characterised by progressive scarring of the lungs. There are no curative treatments for IPF
and survival rates are two to four years upon diagnosis.4 The involvement of αvβ6 in the initiation
and progression of IPF motivates research to understand the conformational changes and binding
properties of αvβ6 with its natural ligand, the pro-domain of TGF-β1, and a series of potential
antagonists.5 Latent TGF-β1 is activated upon binding to integrin αvβ6 through an Arg-Gly-Asp
(RGD)LXX(I/L) motif (where X is any amino acid) in the pro-domain. Activated TGF-β1 responds
to tissue injury, infection and mediates tissue repair. However, increased activity leads to tissue
inflammation and scar formation in uninjured areas.6,7 A drug antagonist of αvβ6 could treat IPF
through active site binding in place of TGF-β1.
Identifying new clinical candidates which balance all necessary properties and that can be
administered as a low dose medicine, is difficult. An important aspect, particularly for the clinical
dose size, is the affinity of the modulator for its biological target. The more potent the molecule is
whilst controlling its lipophilicity, the greater the chance of a lower clinical dose. This study lays
the foundation for computationally estimating the affinity of an inhibitor for the αvβ6 integrin. Pre-
dicting ligand affinity in integrin drug discovery from docking studies has historically been difficult
(although it is generally possible to rationalise the activity once the data is available8). Therefore,
understanding which structural features of the inhibitor are most important for driving affinity from
molecular simulations complements the empirical process that is generally used in integrin lead
optimisation where compounds are made, tested and structure activity relationships (SAR) are
developed. Computational predictions become particularly important with longer syntheses, which
use considerable resources and take months to complete.
The αv subunit of extracellular αvβ6 comprises a lower and upper calf domain, the thigh
domain and the V-propeller domain (Figure 1). Extracellular β6 is made up of a lower leg, upper
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leg, and head region. The head region consists of the plexin-semaphorin-integrin (PSI) domain, the
hybrid domain and the β1 domain. Ligand binding occurs at the interface of the αv and β6 subunit,
with interactions formed between the ligand and each of the head regions (Figure 1). The activity
of αvβ6 is influenced by conformational changes in the multidomain subunits of the integrin. In
its inactive bent-closed conformation, the subunits hinge at each Genu, so that the head regions
fold towards the cell membrane. Activation involves a switchblade-like opening motion of the
upper domains to give the extended-closed conformation, exposing the active site to ligand binding.
A swing out motion of the hybrid domain away from the αv subunit induces the extended-open
conformation. This results in a more closed binding site at the other end of the β1 domain.
Figure 1: Schematic showing the different conformations of αvβ6. The domains of the integrin
are labelled with the extracellular protein shown above the membrane (denoted as a pink strip); the
ligand is shown in orange.9 [Reproduced with permission from ref 9.]
Pro-TGF-β1 binds to αvβ6 through an RGD motif. The ArgRGD side chain interacts with the
carboxyl group on (αv)-Asp218 through bidentate hydrogen bonds (Figure 2a). The carboxyl group
on AspRGD coordinates with a Mg2+ ion in the metal ion-dependent adhesion site (MIDAS) of the
β6 subunit. As these interactions are consistent across all αv integrins bound to RGD ligands,
we term this set of interactions as canonical interactions. The Mg2+ ion is flanked by two Ca2+
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ions, one of which is called the adjacent to MIDAS (ADMIDAS). The MIDAS and ADMIDAS are
important contributors to ligand binding and conformational rearrangements of the receptor. The
opening of the hybrid domain to give the extended-open conformation results in a 3 Å movement
of the ADMIDAS towards the MIDAS.9 This concerted movement decreases the accessibility of
the binding site in the extended-open conformation. The X-ray crystal structure with Protein Data
Bank (PDB) code 4UM910 has been selected for our study. In this structure, αvβ6 is in complex
with TGF-β1 and has a complete MIDAS and ADMIDAS occupancy. In addition to the canonical
interactions displayed in the crystal structure, there are other binding site contacts. The RGD
aspartate on the ligand forms hydrogen bonds with (β6)-Asn218 and (β6)-Ala126 in the receptor.
The backbone of the ligand and (β6)-Thr221 also interact.
By taking advantage of non-canonical intramolecular interactions determined throughmolecular
dynamics (MD) simulations, Di Leva et al. identified a αvβ6 potent cyclic peptide from an RGD-
containing linear oligomer.12 This illustrates the utility of MD simulations for identifying potential
areas for ligand development through a detailed description of how the dynamic changes of active site
residues contribute to receptor-ligand binding. A computational study of αvβ3 - ligRGD complexes
found the ArgRGD - (αv)-Asp218 interaction is maintained over 100 ns.13 Over the simulation
the distance between AspRGD and the Mg2+ ion in the MIDAS of β3 decreased, indicating these
interactions are stable. Another MD simulation study14 revealed, by varying isoDGR-containing
cyclopeptides in complex with αvβ3, subtle differences in αvβ3-ligand interactions that affect the
allosteric response of the receptor to ligand binding.
Our interest focuses on an RGD mimetic as the framework for a series of potential antagonists,
as shown in Figure 2b. A 1,2,3,4-tetrahydro 1,8-naphthyridine group at one end of the compound
mimics the Arg residue in the RGD tripeptide. This moiety is of particular interest in medicinal
chemistry as 1,8-naphthyridines and their derivatives are found in many natural substances with
biological activities.15 The carboxyl on the opposite end of the compound mimics the Asp residue
and binds to the Mg2+ MIDAS ion. Each compound varies at the 3-position of the aryl group,
with substituents including H, F, CF3, OCF3, CH3 and OCH3. These compounds were taken from
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Figure 2: TGF-β1 (a) and the RGD mimtetic (b) bound in the active site of αvβ6, showing the αv
subunit (teal), the β6 subunit (faded green), the backbone of the ligands (maroon) and heteroatoms
(blue and red). The RGD sequence of TGF-β1 is shown in bold. The bidentate (αv)-Asp218
hydrogen bonding and the metal chelate interaction with the Mg2+ ion (orange) are indicated by
dashed lines. The Ca2+ ions are shown in green. Image generated with the PyMol Molecular
Graphics System.11
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a class of compounds in an ongoing study of the SAR of αv integrin antagonists.5,16 Although
other chemotypes have been explored in literature,8,17 our study focuses on a single scaffold.
Scaffold substituents were chosen in our study as they are compatible with the CHARMM force
field, obviating the need for extensive force field development for individual compounds. In
previous work, the activity of each compound has been measured through a cell adhesion assay.
The compounds have pIC50 values in the range of 5.2 to 7.1. Due to the racemic nature of the
compound, a single pIC50 value is assigned to both the (R)- and (S)-enantiomer of each compound,
with the exception of CF3. As the CF3 analogue was prepared from commercially available (R)
and (S) precursors, distinct pIC50 values can be assigned to each enantiomer. pIC50 is the negative
log10 of the half maximal inhibitory concentration (IC50) of a compound. We can relate IC50 to
Δ using Equation 1.
Δ = −') ln (IC50) (1)
In this study, we build on previous calculations18 using molecular docking. Starting from
docked conformations, we use MD and free energy perturbation (FEP) simulations19 to assess the
effects of the different aryl substituents on active site interactions. There is growing interest in
predicting relative binding energies using FEP simulations and integrating them into drug discovery
workflows.20 Chemically accurate in silico binding affinities can provide guidance when optimising
lead compounds, saving synthetic resources and effort. There is a question, however, about the
ease with which FEP can be applied to new systems. Nevertheless, with improved force fields
and greater computational resources becoming more available, FEP simulations are increasingly
attractive and tractable.
The accuracy of FEP simulations rely on a quality force field, sufficient sampling and a well
equilibrated system. This poses some practical considerations. For example, force field param-
eter optimisation may be necessary. For convergence of the predicted free energy change for a
transformation, it is important that at each alchemical perturbation between two end states, the
system is equilibrated to that intermediate state. Also, as perturbations need to be conservative,
many windows may be needed to cope with the change between the two end states. As a result,
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these simulations can become computationally intensive and access to parallel computing systems
is required for thorough sampling regimes at realistic timescales.
In this study, MD simulations of αvβ6 in complex with its natural ligand, TGF-β1, enable
us to investigate the dynamic and thermodynamic behaviour of ligand binding. We identify the
contributions of active site residues to binding bymonitoring how often they interact with the ligand.
MD simulations are also performed for αvβ6 in complex with each of the RGDmimetic derivatives.
We investigate how different substituents and their enantiomers affect active site interactions of the
potential antagonist with αvβ6. Furthermore, to calculate the difference in binding free energy
between derivatives of the scaffold, FEP simulations have been performed on pairs of the RGD
mimetics with each of the substituents.
Methods
Parameter Development
All simulations were performed using the CHARMM force field.21 The CHARMM General Force
Field (CGenFF) is an extension which contains parameters for small drug-like molecules.22 How-
ever, not all atom types in the RGD mimetic, specifically the 1,2,3,4-tetrahydro 1,8-naphthyridine
group, exist within CGenFF. Parameters consistent with the CHARMM force field have been de-
veloped herein to enable the computational study of the potential αvβ6 antagonists. Parameters
were optimised according to the procedure outlined by Vanommeslaeghe et al.23,24
The CHARMM force field consists of a collection of terms, which describe the potential energy
of a system. Parameters in the force field, such as partial charges and equilibrium values of bond
lengths, angles and dihedral angles, can be developed and optimised based on unique atom types.
As not all atom types in our parent compound pre-existed within the force field, initial guesses
for parameters were obtained using a CGenFF atom typing program.23,24 Penalty scores were
generated based on the level of optimisation required for these guess parameters. Basic validation
is recommended for penalties between 10 and 50, and extensive optimisation is necessary for
7
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penalty scores above 50. For computational efficiency, the scaffold was split into three fragments
(Figure 3) and guess parameters were generated for each one. As fragment 1 was the only fragment
to return penalty scores above 10, we concentrated our optimisation efforts on the partial charges







































Figure 3: Fragments 1, 2 and 3, derived from the scaffold of the potential αv antagonist. Atom
labels correspond to those used in the parametrisation process.
Target data were generated by performing quantum mechanical (QM) calculations, using
QChem.25 Following Vanommeslaeghe et al., for each possible hydrogen bonding interaction, a
complex was built of theMP2/6-31G* optimised fragment and a single water molecule in the TIP3P
geometry.26 The water molecule was initially placed in an “ideal" position for hydrogen bonding
and the interaction distance was optimised at the HF/6-31G* level. QM values were compared
with interaction distances and energies obtained from energy minimisations of the same complexes
using the initial guess parameters. Partial charges were optimised so that model fragment-water
interaction energies are within 0.2 kcal mol−1 and distances are within 0.1 Å of the target data.
Bond length and angle parameters were optimised so that values from MP2/6-31G* optimised
fragments were replicated by energy minimisations using the force field. Penalty scores for initial
8
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guess parameters indicated that, for fragment 1, one bond length and several bond angle parameters
required attention. The penalty score for N1-C9 bond length parameters was 145. Therefore,
the force constant and equilibrium terms were modified until the CHARMM energy minimised
length was within 0.03 Å of the MP2/6-31G* optimised structure. All bond angle parameters were
optimised so that the angles were within 3◦ of the MP2/6-31G* optimised structure.
Due to the pseudo-planarity of fragment 1, the only parameterswhich required optimisationwere
those for the N1-C8-C7-C6 torsion. Optimisation of dihedral angle parameters used the MP2/6-
31G* potential energy surface (PES) as target data. The initial method employed to generate the
QM surface involved an optimisation with the dihedral angle constrained and using the resulting
conformation for the subsequent dihedral optimisation. However, this produced irregularities in the
PES, due to the ring flip as the dihedral angle passed through 0◦. To obtain a smooth PES, geometry
optimisations were performed using a planar initial structure for each new dihedral constraint. The
potential energy term describing rotation around a dihedral angle in the CHARMM force field
features parameters for the force constant,  j, the multiplicity, = and the phase X. The same
scan was carried out using the CHARMM force field, with these dihedral parameters set to zero.
A Monte-Carlo Simulated Annealing (MCSA) protocol27 with exponential cooling was used to
minimise the root mean square error between the QM and molecular mechanics (MM) energy
profiles.
To test howwell existingCHARMMforce field parameters describe the ligand derivative penalty
scores for an aryl ring, with each of the substituents attached in turn, were obtained. From these
scores, optimisation of partial charges on the CF3 derivative was considered necessary. Dihedral
angle parameters were also validated for the C-O-C-F torsion on the OCF3 derivative. No further
optimisation was needed for any other aryl substituents used in this study.
Docking
Coordinates were taken from an X-ray crystal structure of a αvβ6 dimer with the pro-domain of
its natural ligand, TGF-β1, bound (PDB code: 4UM9).10 To prepare for docking, chains C, D
9
Page 10 of 37
ACS Paragon Plus Environment





























































and F were extracted from the equilibrated structure with all water molecules and ions removed
(equilibration methodology outlined below). Using receptor generation software as part of the
OpenEye docking toolkit,28,29 Chain F (TGF-β1) was assigned as ligand and thus did not interact
with the docked molecules. A box centred on (β6)-Thr221 with sides of length 21.0 x 22.7 x 27.3
Å was situated to fully cover the TGF-β1 occupied binding site, giving a total receptor volume
of 8680 Å3. Constraints were then applied, ensuring a metal chelate interaction with MIDAS and
hydrogen bond donors to both of the carboxyl oxygen atoms on the (αv)-Asp218 residue.
Compounds were protonated according to physiological pH. The compounds studied were
prepared using OMEGA,29 for both (R) and (S) enantiomers. Conformers were generated using a
truncated form of theMMFF94s force field,30 a variant that excludes both Coulomb interactions and
the attractive part of van der Waals interactions. A maximum energy difference of 20 kcal mol−1
was allowed from the lowest energy conformer. These allowed molecules to explore additional
conformational space. A maximum of 10,000 conformers per enantiomer was set and conformers
within 0.5 Å of any others were considered duplicate and thus removed. Docking was performed
using OpenEye FRED.28 Compounds were docked using the high resolution setting with rotational
and translational step sizes of 1 Å. Chemgauss4 was used to score the poses. The poses of each
enantiomer were inspected for anomalies and the top scoring poses were chosen as the starting
positions for MD simulations.
Molecular Dynamics Simulations
Coordinates of chains C and D were used as starting structures for subunits αv and β6 respectively.
Simulations involving the natural ligand used chain F coordinates. All water molecules and
metal ions throughout the crystal structure were included. It is particularly important to retain
crystallographic water molecules for FEP simulations as they stabilise the system and improve
the equilibration process.20 In accordance with physiological pH, the zwitterion form of the RGD
mimetic was used, with the 1,2,3,4-tetrahydro 1,8-naphthyridine protonated and the carboxyl group
deprotonated. The protonated states of arginine and lysine residues were used and all aspartic and
10
Page 11 of 37
ACS Paragon Plus Environment





























































glutamic acids were deprotonated. Histidine residues were treated as neutral, with the nitrogen atom
nearer the backbone protonated. Procedures to build hydrogen atoms, solvate the system and apply
periodic boundary conditions were generated using the quick MD simulator module in CHARMM-
GUI.31 The systemwas solvated in a truncated octahedral periodic boundary cell with edge distances
of 10 Å to construct an explicitly modelled solvent consisting of 16,886 TIP3P water molecules,26
eight Mg2+ and four Cl− ions, to give a net neutral charge. The concentration of the counter ions
matched conditions used in cell adhesion assays performed on these complexes. To optimise the
solvent positions, all heavy atoms were fixed, except for water molecules, during 50 steps of steepest
descent (SD) and 50 steps of Adopted Basis Newton-Raphson (ABNR) minimisation. Protein and
metal ion parameterswere obtained from theC36 version of theCHARMMforce field.32 Parameters
for metal ions were developed and validated by Beglov et al.33 and are commonly employed in
biomolecular studies.
Upon system setup, the NAMD software34 was used for simulations of all complexes. Firstly,
the solvated crystal structure, still containing TGF-β1, was minimised for 20 ps using a conjugate
gradient and line search algorithm. Protein backbone and side chain restraints were applied using
harmonic constraints with force constants of 10 kcal mol−1 Å−2 and 5 kcal mol−1 Å−2. The system
was heated to 298 K in increments of 3 K every 1 ps using NAMDvelocity reassignment. Backbone
and side chain restraints were gradually switched off during a 2 ns equilibration period in the NVT
ensemble. The coordinates of the equilibrated receptor were used for ligand docking.
To ensure canonical interactions were maintained during an additional 1 ns equilibration of the
docked complexes, both carboxyl oxygen atoms on the aspartate mimetic were constrained to a
distance of 2 Å from the Mg2+ ion. The polar hydrogen atoms on the protonated 1,2,3,4-tetrahydro
1,8-naphthyridine segment were constrained to a distance of 2 Å from the carboxyl oxygen atoms on
(αv)-Asp218. An initial force constant of 10 kcal mol−1 Å−2 was used for all distance constraints.
Force constants for distance constraints were steadily decreased to 2.5 kcal mol−1 Å−2 during
an equilibration of 0.5 ns in the NVT ensemble and 0.5 ns in the NPT ensemble. This meant
all canonical interactions were present at the start of production runs. Five independent 10 ns
11
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production runs were performed in the NPT ensemble for the (R)- and (S)-enantiomers of each
derivative. Simulations of αvβ6 bound with TGF-β1 were also performed, resulting in a total of
65 simulations of 10 ns. Temperature was controlled using Langevin dynamics parameters, with
a friction coefficient of 5 ps−1 for all equilibration and production runs. Constant pressure was
maintained using the Langevin piston Nosé-Hoover method35 with a target pressure of 1 atm. A
cutoff distance of 12 Å was used for van der Waals pairs, with a switching function at a distance of
10 Å. The electrostatic potential energy was computed using the Particle Mesh Ewald method.36
The SHAKE algorithm37 was used to fix all bond lengths involving hydrogen atoms and a timestep
of 2 fs was used. Upon completion of production runs, all solvent molecules were removed except
those within 10 Å of the ligand, in order to expedite the analysis. Trajectories were sampled every
20 ps, resulting in 500 frames for each replica.
Free Energy Perturbation Simulations
FEP simulations involve an alchemical transformation between two structurally related ligands.19
A change is made to the system so that the potential energy is equivalent to the original potential
energy with an additional “perturbing" potential energy term (+):
* = * ++ (2)
where* and* are the respective potential energies of state A and B, which represent the states
where a different ligand is bound in each. States A and B should arise from the same conformational
space and therefore, + needs to be very small. To address this, the transformation of A to B is
divided into several discrete simulations, called windows, which are connected using a coupling
parameter, _.
Figure 4 shows the thermodynamic cycle of a transformation of the hydrogen derivative of the
RGD mimetic (state A) into the methoxy derivative (state B). Δ1 and Δ2 are the binding free
energies of each ligand, while Δ3 and Δ4 are the free energies of transforming one ligand into
12
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the other, as the free ligand and in complex with the receptor. At each end point of the simulation
(ligand A and ligand B) _ equals zero or one. At intervals between these end points, bonded
and non-bonded parameters are scaled so that they are “switched off" for outgoing atoms and
“switched on" for incoming atoms. There are two ways to alchemically mutate ligands. The single
topology approach38 uses dummy atoms for appearing/disappearing atoms, while gradually scaling
parameters so that relevant atoms of the initial ligand are turned off and they become dummy atoms.
The nature of this method means that, although transformations converge better, it cannot cope with
large changes in ligands. In the dual topology approach,39 the topology of the mutating species
contains both ligands simultaneously. Intermolecular interactions are turned on for one ligand as
they are turned off for the other. Typically, a dual topology method is easier to use and can cope
with larger changes in ligands compared to the single topology method.40 In our FEP simulations,
we employ the dual topology approach.
Figure 4: Thermodynamic cycle describing the binding of two ligands. Δ1 and Δ2 represent
the free energy of binding of two ligands. Δ3 and Δ4 describe the free energy change of an
alchemical transformation of one ligand into the other, as the free ligand in solution and bound
to the receptor, respectively. The relative free energy of binding of two ligands is the difference
between the alchemical free energy changes.
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A soft-core potential is used to avoid “end-point catastrophes", where disappearing atoms can
leave empty pockets and appearing atoms clash with the existing environment.41,42 This eliminates
the singularities at each end point by progressively scaling interactions of outgoing atoms and
incoming atoms. The short range repulsive term in the standard Lennard-Jones potential is scaled to
allow “soft" overlap of van derWaals spheres at regions surrounding incoming and outgoing atoms.
The Coulombic term in the potential is also scaled to avoid abnormal electrostatic interactions
between the softened atoms and their environment. Electrostatic interactions of outgoing atoms
are decoupled from the system over the _ range of 0 to 0.5, while the electrostatics for incoming
atoms are coupled to the system over the _ range of 0.5 to 1.
To calculate relative binding free energies of pairs of ligands, ten different alchemical transfor-
mations of aryl substituents were performed. For each perturbation, three replicas of the forwards
and backwards transformation were performed, resulting in 60 FEP simulations. Ahead of system
setup, dual topologies were constructed for both the free and bound ligands. To prevent system
drift, caused by the charged ends of the free ligand coming together, the transformations of the free
ligand in solvent started from structures close to an energy minimised conformation. The setup
of systems and free energy simulations were performed using the procedures for the standard MD
simulations described above. During FEP, _ was increased from 0.0 to 0.1 in 16 discrete steps,
from 0.1 to 0.9 in steps of 0.02 and from 0.9 to 1.0 in 16 steps to give a total of 72 windows for
each transformation. Equilibration was performed for 20 ps at the start of each window, followed
by 100 ps of sampling.
Results and Discussion
Parameter Development
For the 1,2,3,4-tetrahydro 1,8-naphthyridine group (fragment 1 in Figure 3), Table 1 shows the
optimised interaction energies and distances for hydrogen bonding interactions with polar atoms
on the antagonist at the HF/6-31G* level, and when using the CHARMM force field once partial
14
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charges were optimised. Interaction energies are within 0.2 kcal mol−1, as recommended by
parameter optimisation methodology.22 Although the interaction distance between the fluorine
atoms on the CF3 derivative and the TIP3P oxygen atom is above the recommended 0.1 Å, similar
disagreement has been acceptable in other major parameterisation efforts.22
Table 1: QM and MM interaction energies and distances of a single water molecule in a hydrogen
bonding interaction with polar atoms on fragment 1 and the CF3 aryl derivative. O represents the
oxygen atom on the TIP3P water molecule. Distances are in Å and energies are given in kcal mol−1.
Interaction HF/6-31G* Optimised CHARMM Parameters DifferenceDistance Energy Distance Energy Distance Energy
H12 - O 2.1 -16.4 2.0 -16.4 0.1 0.0
H13 - O 2.0 -16.2 1.9 -16.4 0.1 0.2
CF - O 2.3 -1.9 2 -1.9 0.3 0.0
Figure 5 shows the MP2/6-31G* bond lengths and partial charges assigned to the methylated
1,8-naphthyridine fragment. The similarity in bond lengths between the central carbon atom and
adjacent nitrogen atoms suggests that the charge delocalisation extends across the ring to include
both nitrogen atoms, rather than a localised aromatic pyridine-piperidine structure. This is reflected
in the partial charges assigned to these atom types in the developed force field parameters (full
parameters can be found in the Supporting Information).
Figure 5: Bond lengths and atomic partial charges calculated at the MP2/6-31G* level for fragment
1. Bond lengths are shown in Å.
Optimised values for the high penalty bond lengths and angles in fragment one are shown inTable
2. These values are also in close agreement with the bond lengths and angles in four naphthyridine
15
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containing molecules43–46 from the Cambridge Crystallographic Data Centre (CCDC)47 (Table S1
in Supporting Information).
Table 2: Bond lengths and angles on fragment 1 from MP2/6-31G* geometry optimisation and
energy minimisation using optimised CHARMM force field parameters. Bond lengths shown in Å
and bond angles shown in degrees.
Bond MP2/6-31G* Optimisation Optimised CHARMM Parameters Difference
N1 - C9 1.34 1.33 0.01
N1 - C9 - N2 119 118 1
C9 - N1 - H12 120 120 0
C9 - N1 - C8 122 119 3
C5 - C9 - N1 123 124 1
Figure 6 shows the potential energy surface of the N1-C8-C7-C6 dihedral angle, calculated
using different methods. There is a closer match between MM and QM surfaces once dihedral
parameters,  , = and X, are optimised using a MCSA protocol. The penalty score returned for the
C-O-C-F dihedral parameters in the OCF3 derivative was 98, implying necessity for optimisation.
However, the QM and MM PES around the torsion indicated a sufficient match between the curves
when using the initial guess parameters; therefore, no optimisation was performed.
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Figure 6: Dihedral scan around the N1-C8-C7-C6 angle showing the MP2/6-31G* surface (dashed
line), the CHARMM initial guess (dotted line) and the CHARMM surface after parameters are
optimised (solid line).
Molecular Dynamics Simulations
Protein-Ligand Interactions of TGF-β1
Polar residues that are important for binding can be identified by investigating the dynamics of
hydrogen bonds between the natural ligand of αvβ6, TGF-β1, and the receptor. From the crystal
structure, it is clear that (αv)-Asp218, (β6)-Ala126, (β6)-Asn218 and (β6)-Thr221 form hydrogen
bonds with TGF-β1. The fraction of time that these interactions were maintained over the 50 ns
MD simulation was measured. A pair of atoms are considered to be hydrogen bonded if a polar
hydrogen atom is within 2.5 Å of an oxygen, nitrogen or fluorine atom. A bidentate interaction
between (αv)Asp218 and the Arg residue of the RGD unit on the ligand was present for 82% of
the simulation time. (β6)-Ala126, (β6)-Asn218 and (β6)-Thr221 were all hydrogen bonded with
TGF-β1 for over 90% of the simulation time. The MD simulation indicated two hydrogen bonds
formed between the Asp residue of the RGD binding tripeptide in the ligand and (β6)-Asn218. One
17
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interaction involved the amide backbone of the (β6)-Asn218 residue for 98% of the simulation time
and the other involved the side chain of (β6)-Asn218 for 66% of the simulation time. The hydrogen
bond with the side chain is not present in the starting structure and is only observed as the result
of dynamics. Both interactions with (β6)-Asn218 are known among RGD ligands and have been
previously recognised.10,48,49 The metal chelate interaction between AspRGD and the Mg2+MIDAS
ion was maintained throughout the entire simulation.
Figure 7 depicts the position of the binding site residues that form hydrogen bonds with TGF-
β1, identified by the crystal structure and MD simulations. Residues (β6)-Ile219 and (β6)-Gln317
are also shown. These do not appear to interact in the crystal structure but are in close proximity
with TGF-β1 for 78% and 7% of the MD simulation time, respectively. This highlights how
MD simulations can identify active site residues that contribute to ligand binding, which are not
observed in a static crystal structure. In an ongoing study, these receptor conformations generated
by MD simulations are being used for docking as a way to extend the receptor conformational
search space and identify further antagonists.
Figure 7: Residues that form interactions with TGF-β1 (maroon backbone) over a 50 ns MD
simulation. Interacting residues in the crystal structure are shown (light green) as well as residues
that do not interact in the crystal structure, but gain an interaction during MD (light blue). The
Mg2+ MIDAS ion (orange) and Ca2+ ions (dark green) are also shown.
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Hydrophobic interactions are also important for the binding of TGF-β1 to αvβ6. The 244-
LGRLK-248 sequence directly following the RGD motif folds into an amphipathic α-helix, which
fits into a β6-specific hydrophobic pocket, as previously reported.10,12,50,51 Leu224 and Leu247 form
lipophilic contacts with this pocket, which is formed by residues distinct to β6 when compared to
other RGD binding members of the integrin family such as αvβ3 and αvβ5.10 Contact between the
amphipathic α-helix of TGF-β1 and the hydrophobic pocket of β6 was maintained throughout the
MD simulations.
Protein-Ligand Interactions of RGD Mimetics
By monitoring the dynamics of hydrogen bonding interactions between each derivative of the RGD
mimetic and the receptor, we characterise the nature of ligand binding. The stability of the canonical
interactions could reflect the potency of each ligand, as an active compound should maintain these
interactions and remain bound in the active site. In principle, there could be a link between
analogues with higher pIC50 values and better maintained canonical interactions. All derivatives
of the pseudo-RGD compound remain bound throughout the MD simulations, through at least
one component of the canonical interactions. Table 3 shows the pIC50 values of each analogue,
which are a measure of activity5 (with additional pharmacological data available in reference 5)
and the fraction of time that the canonical interactions were maintained. The interaction frequency
is the proportion of frames with the interaction present with respect to the total number of frames,
averaged over five 10 ns simulations. The bidentate interaction is present in all derivatives of the
RGD mimetic to a varying extent. However, there is no correspondence between the stability of
the bidentate interaction and pIC50.
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Table 3: Interaction frequency in % of simulation time that the bidentate, Mg2+ - O1 and Mg2+ - O2
interactions are maintained for each analogue of the RGD mimetic. Contact frequencies between
atoms on the aryl rings and active site residues are also shown in columns 8-10. The experimental
activity of each analogue is shown by its pIC50 value.5 The molecular docking score (arbitrary
units), generated using OpenEye FRED28 and OpenEye OMEGA,29 is also shown.
Interaction Frequency (% Time)
Substituent Enantiomer pIC50 Docking Score Bidentate Interaction Mg2+ - O1 Mg2+ - O2 (β6)-Ser127 (β6)-Ala126 (β6)-Ile219
H S 5.7 -9.99 89 100 0 96 8 20R -9.19 96 100 100 24 24 0
F S 6.1 -9.64 96 100 46 50 22 2R -9.29 29 89 80 39 23 5
CH3
S 6.4 -7.96 100 100 73 81 38 49R -4.64 100 100 100 47 43 2
OCH3
S 6.5 -9.38 65 100 100 100 62 0R -6.57 100 100 100 84 3 0
OCF3
S 6.7 -8.49 98 100 40 45 19 0R -3.59 99 100 0 0 0 3
CF3
S 7.1 -9.33 74 100 100 57 43 25
R 5.2 -5.70 19 100 100 0 0 3
The loss of the bidentate interaction is caused by a slight overall translation of the ligand in
the binding site so that only one polar hydrogen atom on the naphthyridine fragment is within
2.5 Å of (αv)-Asp218. Although the bidentate interaction is lost for a considerable amount of
time in some ligands, a monodentate interaction between the Arg mimetic and (αv)-Asp218 is
commonly observed for all ligands (Table S2 in the Supplementary Information). All analogues
of the ligand form at least one metal chelate interaction with the Mg2+ ion throughout the MD
simulations. The difference between interactions Mg2+ - O1 and Mg2+ - O2 is the oxygen atom on
the carboxyl group that the Mg2+ interacts with. Given the proximity of the chiral centre to the
MIDAS site, it might be expected that interaction frequencies for the less active enantiomer with
MIDAS amino-acid residues will be lower as the calculations suggest. Given the conformational
flexibility of the molecule however, what is less expected is the impact on the bidentate interaction
frequency between (αv)-Asp218 and the 1,8-naphthyridine at the other end of the molecule which
is much lower for the less active enantiomer compared to the more active enantiomer (R-CF3 19%
and S-CF3 74%). Nevertheless, the interaction with the MIDAS ion is better maintained than the
bidentate hydrogen bond in all cases. Therefore, we observe that the stability of the metal chelate
interaction between AspRGD and the Mg2+ ion is more important than the bidentate hydrogen
bonding to (αv)-Asp218 for ligand binding.
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The position of the aryl ring on the bound ligand is indicated in Figure 8. The metal chelate
interaction formed by the carbonyl and Mg2+ MIDAS ion points inwards into the binding pocket,
forcing the aryl ring to become solvent exposed. Nearby residues are on the β1-α1 and α2-α3
loops, specifically (β6)-Ala126, (β6)-Ser127, (β6)-Asn218, (β6)-Ile219, (β6)-Asp220 and (β6)-Thr221.
The side chain of (β6)-Ala126 and the backbone of (β6)-Asn218 contribute to the β6 hydrophobic
binding pocket.10 All (S)-enantiomer derivatives of the ligand show an interaction with both groups
(Table S2). Further contacts within 2.5 Å of each substituted ring and any atom on the β6 unit were
investigated. Table 3 shows the frequency of contacts with (β6)-Ala126, (β6)-Ser127 and (β6)-Ile219.
From the proximity of the ring to (β6)-Ser127, we observe that the (S)-H, (S)-CH3 and (S)-OCH3
derivatives remain in close contact with the β1-α1 loop. The remaining S-derivatives, (S)-CF3,
(S)-F and (S)-OCF3, stay close to the β1-α1 loop, but for less than 50% of the simulation time. As
no other contacts are formed between these derivatives and the receptor for a significant amount of
time, we suggest that solvent interactions with these more polar substituents influence the position
of the aryl ring.
Figure 8: Position of the aryl ring on the (S)-RGDmimetic within the binding site. Nearby residues
on the β1-α1 and α2-α3 loops (green) are labelled. The oxygen atoms of water molecules within
7 Å of the ring are also shown (red spheres).
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MD simulations of the natural ligand, TGF-β1, indicated that residues (β6)-Ala126, (β6)-
Thr221 and (β6)-Asn218 in the receptor are all involved in binding. Therefore, hydrogen bonding
interactions between these residues and the RDGmimetics were investigated. The carboxyl oxygen
atoms on the (S)-forms of the H, F, CH3 and OCF3 derivatives interacted with (β6)-Ala126 for
67%, 45%, 10% and 60% of the simulation time, respectively. No stable interactions are identified
between any derivatives of the ligand and (β6)-Thr221. Although interactions between the ligands
and residue (β6)-Thr221 are present in the docked structures, they are lost during equilibration of the
systems and are not observed during dynamics. In the docked structures, (β6)-Thr221 interacts with
the carbonyl oxygen atom on the amide backbone of the ligand. However, during equilibration, the
carboxyl group rotates away from the receptor to become more solvent exposed.
Cation-π interactions in αvβ6-RGD systems
A cation-π interaction consists of an electrostatic attraction between an electron rich aryl ring and
an electron deficient cation. This type of interaction is common in proteins; an early data mining
study of a subset of the PDB found that over 70% of all Arg side chains are near an aromatic side
chain.52 The crystal structure of αvβ6 - TGF-β1 is no exception, with a face-to-face intermolecular
cation-π interaction between ArgRGD and residue (αv)-Tyr178 (Figure 9). A mixture of factors
govern cation-π interaction orientation, such as competitive hydrogen bonding and the influence of
solvent.53 However, this parallel geometry is more common in proteins than T-shaped geometries,
although T-shaped geometries are preferred in the gas-phase.52,54 To monitor the persistence of
the cation-π interaction during MD, the distance between the cationic Arg group (the guanidinium
carbon in Arg) in TGF-β1 and the centre of the aromatic (αv)-Tyr178 ring was measured. A distance
less than 5 Å, a common geometrical constraint used in previous studies, indicated an interaction.
The average distance between the two residues was 4.41 Å with a standard deviation of 0.48 Å. The
face-to-face geometry was also maintained throughout.
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Figure 9: Cation-π interactions between the cationic nitrogen atoms on ArgRGD (left) or the 1,2,3,4-
tetrahydro 1,8-naphthyridine group of the (S)-CF3 derivative (right) and the aromatic side chain of
(αv)-Tyr178.
As the overarching aim is to design a compound that competitively binds with αvβ6, it would be
sensible to take advantage of the position of (αv)-Tyr178 and replicate this cation-π interaction with
the RGD mimetics. The cation in this case is the protonated 1,2,3,4-tetrahydro 1,8-naphthyridine
group. Although the interaction between the naphthyridine group, an aromatic cation, and the
aromatic side chain of (αv)-Tyr178 could be dominated by π-π interactions, a study by Tsuzuki
et al.55 found, through high level ab initio calculations, that interactions of benzene complexes
with aromatic cations should be categorised as cation-π interactions as they are stabilised by large
electrostatic and induction interactions. The distance between the positively charged nitrogen atom
and the centre of the aromatic (αv)-Tyr178 ring was measured for each of the RGD derivatives.
Table 4 shows the distances, averaged over 10 ns of MD. The majority of compounds had an
average distance within the 5 Å cutoff. The cation-π interaction orientation sampled most was a
face-to-face geometry of the (αv)-Tyr178 side chain with the naphthyridine group (Figure 9). Thus,
the RGD mimetics replicate this type of interaction seen with TGF-β1, in addition to the canonical
hydrogen bonding interactions.
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Table 4: The distance between the protonated N atom on each RGD derivative and the centre of the
aromatic ring on (αv)-Tyr178. Distances have been averaged over 10 ns of MD simulations, with
the standard deviation shown.
Substituent NH+ - Tyr178 Distance (Å)
(S)-H 3.77 ± 0.33
(R)-H 5.01 ± 0.86
(S)-F 4.80 ± 0.41
(R)-F 4.78 ± 1.06
(S)-CH3 4.63 ± 0.43
(R)-CH3 4.13 ± 0.50
(S)-OCH3 3.82 ± 0.47
(R)-OCH3 4.21 ± 0.49
(S)-OCF3 5.21 ± 0.44
(R)-OCF3 5.33 ± 0.69
(S)-CF3 4.19 ± 0.62
(R)-CF3 4.33 ± 0.50
Free Energy Perturbation Simulations
To assess the convergence of the alchemical calculations, a method outlined by Klimovich et al56
was used. In our example (Figure 10) we consider the transformation of a hydrogen substituent to
an OCF3 substituent, with the ligand in the bound state. This transformation was chosen as it is the
most diverse in terms of the number and types of atoms perturbed and therefore, it might be most
likely to have convergence issues. The free energy change is calculated using an increasing fraction
of the simulation data (i.e. 0-0.1, 0.0-0.2). Also plotted in Figure 10 is the free energy change
calculated with the reverse proportion of the data (i.e. 0.9-1.0, 0.8-1.0). Both sets of data remain
within error of the final value and so the calculation is considered converged. Furthermore, the
relative free energies of the forwards and backwards transformations were compared, as the values
are expected to be identical but of opposite sign. The H→ OCF3 perturbation of the free ligand
gave a relative free energy change of -8.9 kcal mol−1, while the OCF3→ H perturbation resulted in
a relative free energy change of 8.5 kcal mol−1. The same perturbations gave relative free energy
changes of -10.4 kcal mol−1 and 9.8 kcal mol−1 when the ligand was bound. The relative free
energies reflect that, due to its stronger non-covalent interactions, the OCF3 derivative is favoured
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over the hydrogen substituent in both solvent and in complex with the receptor. The similarity for
the forwards and backwards transformation in both states suggests that conditions are met for the
convergence of the alchemical simulations.
Figure 10: Convergence assessment of the transformation of the hydrogen derivative to the OCF3
derivative, with the ligand in the bound state. The forward (black line) and the reverse (green line)
simulation time series are shown. The horizontal grey strip indicates the equilibrated region.
Calculated relative free energies of binding are shown in Table 5. The Δ values for the
transformations of the free ligand and in complex with the receptor were evaluated with the
Bennett Acceptance Ratio (BAR) method,57 using the ParseFEP tool in VMD.58 ΔΔ values
were obtained by taking the difference between each of these transformations. These theoretical
values are compared with ΔΔ values obtained from the experimental pIC50 values. For all ten
alchemical transformations, the sign of the relative free energy difference is correctly predicted,
although the magnitude is almost always over-estimated but in a non-systematic manner. As all
derivatives, with the exception of CF3, were measured as racemic mixtures, there is a probable
±0.3 log error on each experimental binding free energy, which should also be taken into account.
The calculated values are in within 1.5 kcal mol−1 of experiment, with the exception of the H→
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CH3, CH3 → OCH3 and OCH3 → OCF3 aryl transformations. In order to compare the results of
the FEP simulations with simpler methods, we investigate the relationship between docking scores
and experimental activity (Table 3). Upon docking of the ligands into the equilibrated receptor,
a score is obtained which reflects the quality of the docking of the RGD mimetic to the αvβ6
binding site. Although the values are somewhat empirical and cannot be directly related to binding
affinity, docking scores can be useful for ranking compounds or distinguishing between active and
non-active compounds.59 The docking scores shown in Table 3 do not correlate with the pIC50
values. Despite this, the scores do consistently indicate that the (S)-enantiomers will be more active
than the (R)-enantiomers, as expected. As the relative free energies obtained for the ligands agree
more closely with experiment, compared to the docking scores, we suggest that a more physically
realistic model has resulted from FEP simulations for this system, albeit at higher computational
cost.
The narrow range of activity exhibited by these ligandsmeans it is difficult to rank the derivatives,
but is not atypical of many such examples in the field.60 The close match between the values for each
of the derivatives shows that FEP calculations model the system well, giving a solid foundation for
the associated analysis. While the equilibriumMD simulations provide information on the dynamic
behaviour of interacting residues (as detailed in Table 3), FEP simulations provide a rigorous
way to quantify various physical factors, such as changes in hydrophobic and hydrogen bonding
interactions. Taking the transformation from the hydrogen derivative to the OCF3 derivative as an
example, the more lipophilic OCF3 substituent is expected to have more favorable interactions with
the hydrophobic binding pocket in the β6 subunit. This is reflected by the experimental free energy
of binding, which shows a difference of -1.4 kcal mol−1 between the two derivatives. Calculated
values show a similar relative binding free energy of -1.9 kcal mol−1. The ability to predict the
free energy of binding means, given a larger range of substituents and attachment points, it could
be possible to rank potential ligands with affinity for αvβ6 and provide guidance on the synthesis
of compounds.
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Table 5: Relative free binding energy of ligand derivatives. Experimental ΔΔ values have an
error of 0.6 kcal mol−1.
ΔΔ (kcal mol−1)
Transformation Experimental Calculated Absolute Difference
CH3→ OCH3 -0.1 -2.6 ± 0.3 2.5
OCH3→ OCF3 -0.3 -2.3 ± 0.3 2.0
H→ F -0.5 -1.9 ± 0.2 1.4
OCF3→ CF3 -0.5 -0.5 ± 0.4 0.0
H→ CH3 -1.0 -2.9 ± 0.3 1.9
CH3→ CF3 -1.0 -1.4 ± 0.3 0.4
H→ OCH3 -1.1 -1.8 ± 0.3 0.7
H→ OCF3 -1.4 -1.9 ± 0.4 0.5
F→ CF3 -1.4 -1.3 ± 0.3 0.1
H→ CF3 -1.9 -2.3 ± 0.3 0.4
Conclusions
In this work, MD and FEP simulations aid the investigation of potential antagonists of αvβ6.
Consequently, CHARMM force field parameters have been developed for 1,2,3,4-tetrahydro 1,8-
naphthyridine. As naphthyridine is an important moiety in medicinal chemistry,15 we expect these
new parameters will find utility in future computational studies. An MD simulation of αvβ6 bound
with the the pro domain of TGF-β1, starting from an X-ray crystal structure,10 was performed in
order to understand the binding site interactions of the natural ligand. MD simulations on a series
of compounds, based on an RGD mimetic, were also performed starting from docked structures.
From these studies the importance of the canonical interactions, the bidentate interaction of the 1,8-
naphthyridinewith (αv)-Asp218 and the acid binding to theMIDAS site, are clear. These interactions
are supported by unpublished SAR which (i) demonstrates the distance between the base and the
acid is critical and (ii) shows that maintaining αvβ6 affinity whilst structurally modifying the acid
and 1,8-naphthyridine is particularly challenging. The calculations suggest the substituted aryl ring
is essentially solvent exposed. Other work5,8,16 has found that about two log units of potency can
be gained with the optimal substituent both with this chemotype5,16 and others,8 but this involves
larger substituents which can form additional interactions with the receptor.
27
Page 28 of 37
ACS Paragon Plus Environment





























































FEP simulations have enabled us to estimate the relative free energies of binding between pairs
of RGD mimetics. As the range in pIC50 of the subset of compounds studied was 5.2 to 7.1, which
is relatively narrow, future work should expand the substituents studied to include more potent
compounds. Furthermore, in order to rank this series of β6 antagonists, all perturbations should
be linked in some way so that the energies can be compared. Therefore, an alternative perturbation
map should be considered. As suggested by Cournia et al.,20 instead of performing perturbations to
each ligand from a single reference compound, substituents should be connected in a single graph,
arranged by similarity. By connecting each substituent to at least two other derivatives in a closed
cycle, it is also possible to compute sampling errors as the total free energy change in a closed
thermodynamic cycle should equal zero. Nevertheless, by comparing the binding free energies
calculated in this study with the difference in pIC50 value for each pair, we have shown that this
integrin system, along with this series of ligands is amenable to study by FEP, with a good level of
accuracy.
From a drug design perspective, lead optimisation of αv integrin inhibitors (αvβ6 inhibitors for
example) has been driven empirically5 and a priori selection of optimal substituents on the carbo-
aromatic is difficult. This is because the current understanding in how the substituted aryl part of
the molecule affects potency and selectivity through interactions with the specificity determining
loop in the binding site is poor.3,5 As a result, lead optimisation requires a large team of synthetic
chemists and substantial budget and can mean progress towards a clinical candidate becomes slow.
There is therefore great value in any method which transitions molecular design from empiricism
to theory, which is reliable.
Based on our previous work,18 large numbers of potential inhibitors can be generated com-
putationally featuring multi-substituted aryl motifs. Whilst this has advantages, multi-substituted
aromatics can be difficult to synthesise which exacerbates what are already often challenging
and long syntheses of the inhibitor. So some additional method to select the best compounds
to make is needed and this illustrates the value of this work as it paves the way towards a more
robust computational prediction of affinity, which should be valuable in prioritising compounds for
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